| Old Articles: <Older 5151-5160 Newer> |
|---|
 |
Chemistry World
October 2008
Paul Docherty |
Column: Totally Synthetic Samuel Danishefsky of Columbia University (and the Sloan-Kettering Institute for cancer research), has focused on function rather than family. His many synthetic conquests are unified by their cancer-busting potential.   |
The Motley Fool
September 30, 2008
Brian Lawler |
Moody's Gets Moody With Drugmakers European pharmaceuticals get a negative rating from Moody's. |
The Motley Fool
September 30, 2008
Brian Lawler |
Novo Nordisk Takes On All Comers Its diabetes franchise is about to get bigger. |
The Motley Fool
September 30, 2008
Brian Lawler |
No Approval for You ... Yet The FDA makes Eli Lilly wait for word on a lead drug. |
The Motley Fool
September 30, 2008
Brian Orelli |
Pharma, Cash, and You Pharma's been saving for a rainy day, and there's a thunderstorm outside. |
The Motley Fool
September 30, 2008
Brian Orelli |
Cardinal Health Clips Its Wings Does it make sense for the drug wholesaler to spin off its medical equipment business? |
The Motley Fool
September 30, 2008
Brian Orelli |
The Lethal Lessons of Eprex The FDA's concerned about J&J's blood-boosting drug. Should investors be, too? |
The Motley Fool
September 29, 2008
Brian Orelli |
An Overnight 2-Bagger A nod from the FDA and a new partnership boost Indevus shares. Where to, now? |
The Motley Fool
September 26, 2008
Brian Lawler |
Less Is More for Vertex The company's potential hepatitis C compound proves effective with fewer dosages. |
The Motley Fool
September 25, 2008
Brian Lawler |
Eli Lilly's Dose of Disclosure The pharmaceutical pledges public reports of its dealings with doctors. |
| <Older 5151-5160 Newer> Return to current articles. |
